| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/30/2002 | CA2104461C Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same |
| 07/25/2002 | WO2002057778A1 Screening assay for cotranslational translocation interfering compounds |
| 07/25/2002 | WO2002057465A2 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 07/25/2002 | WO2002057454A2 Receptors and membrane-associated proteins |
| 07/25/2002 | WO2002057427A2 Mammalian tumor susceptibility gene products and their uses |
| 07/25/2002 | WO2002057425A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/25/2002 | WO2002057413A2 Peptides for activation and inhibition of delta pkc |
| 07/25/2002 | WO2002057306A1 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| 07/25/2002 | WO2002057300A1 Regulated activation of cell-membrane receptors by metal-chelating agonists |
| 07/25/2002 | WO2002057287A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/25/2002 | WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors |
| 07/25/2002 | WO2002057256A1 Piperazinylcarbonylquinolines and -isoquinolines |
| 07/25/2002 | WO2002057239A2 Pyrimidine phosphorylase as a target for imaging and therapy |
| 07/25/2002 | WO2002057233A1 Mch antagonists and their use in the treatment of obesity |
| 07/25/2002 | WO2002056912A2 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
| 07/25/2002 | WO2002056902A2 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 07/25/2002 | WO2002056899A1 Compositions and methods for reducing oxysterols in blood |
| 07/25/2002 | WO2002056894A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent |
| 07/25/2002 | WO2002056891A1 Regulation of glucocorticoid concentration |
| 07/25/2002 | WO2002056890A1 Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 07/25/2002 | WO2002056884A2 Treatment of malaria with farnesyl protein transferase inhibitors |
| 07/25/2002 | WO2002056878A2 Pharmaceutical composition having reduced tendency for drug crystallization |
| 07/25/2002 | WO2002056875A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 07/25/2002 | WO2002056874A2 Lipid-based nitric oxide donors |
| 07/25/2002 | WO2002056873A2 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues |
| 07/25/2002 | WO2002056872A2 Antiproliferative colchicine compositions and uses thereof |
| 07/25/2002 | WO2002056871A2 Histamine receptor antagonists |
| 07/25/2002 | WO2002056864A2 Differential delivery of nitric oxide |
| 07/25/2002 | WO2002056826A2 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 07/25/2002 | WO2002056823A2 Redox therapy for tumors |
| 07/25/2002 | WO2002056804A2 Presbyopia treatment by lens alteration |
| 07/25/2002 | WO2002056790A2 Delivery of therapeutic capable agents |
| 07/25/2002 | WO2002056753A2 P27 prevents cellular migration |
| 07/25/2002 | WO2002056745A2 Method of treating parkinson's disease |
| 07/25/2002 | WO2002056692A1 Methods for modulating tumor growth and metastasis |
| 07/25/2002 | WO2002043652A3 Anti-proliferative drugs |
| 07/25/2002 | WO2002039988A3 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 07/25/2002 | WO2002039879A3 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| 07/25/2002 | WO2002038107A3 Stat modulators |
| 07/25/2002 | WO2002036591A3 Inhalative solution formulation containing a tiotropium salt |
| 07/25/2002 | WO2002036071A3 Method of treating and preventing migraine headaches |
| 07/25/2002 | WO2002032874A3 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/25/2002 | WO2002020615A3 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 07/25/2002 | WO2002020466B1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/25/2002 | WO2002015886A3 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002015884A3 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002014489A3 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 07/25/2002 | WO2002014320A3 Novel substituted diaryl azepine derivatives as integrin ligands |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2002006306A3 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY |
| 07/25/2002 | WO2002005849A3 Transportation of nucleic acid substances |
| 07/25/2002 | WO2002002147A3 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 07/25/2002 | WO2001097872B1 Bioadhesive compositions and methods of preparation and use |
| 07/25/2002 | WO2001093865A3 Medicaments for treating dementia |
| 07/25/2002 | WO2001092891A3 Regulating lipid levels via the zmax1 or hbm gene |
| 07/25/2002 | WO2001087307A3 Compositions and methods for the treatment of cancer |
| 07/25/2002 | WO2001082919B1 Methods of and compounds for inhibiting calpains |
| 07/25/2002 | WO2001080894A3 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| 07/25/2002 | WO2001078781A9 Methods for prevention and treatment of gastrointestinal disorders |
| 07/25/2002 | WO2001074346A3 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 07/25/2002 | WO2001070222A3 Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 07/25/2002 | WO2001068073A8 Method for improving respiratory function and inhibiting muscular degeneration |
| 07/25/2002 | WO2001062289B1 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 07/25/2002 | WO2001060992A3 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 07/25/2002 | WO2001045690A3 Use of bvdu for inhibiting the growth of hyperproliferative cells |
| 07/25/2002 | WO2001034201A9 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 07/25/2002 | WO2001032186A3 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 07/25/2002 | WO2001015676A3 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 07/25/2002 | WO2001007056A9 Method of promoting bone growth with hyaluronic acid and growth factors |
| 07/25/2002 | WO2001004157A9 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 07/25/2002 | WO2001003716A9 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 07/25/2002 | WO2001002567A9 16405 receptor, a g-protein coupled receptor |
| 07/25/2002 | WO2000059486A8 Use of cyp2d6 inhibitors in combination therapies |
| 07/25/2002 | US20020100069 Treating heart defects; obtain tissue, incubate with modulator of transcription, evaluate tissue for defect |
| 07/25/2002 | US20020099191 EDG8 receptor, its preparation and use |
| 07/25/2002 | US20020099169 Modulation of preferential transcription factor; obtain sample containing transcription factor, incubate with modulator, monitor transcriptional activity |
| 07/25/2002 | US20020099100 Treatment of dry eye syndrome |
| 07/25/2002 | US20020099095 For treatment and prophylactic treatment of ageing of the skin, for pretreatment or after-treatment of hair or scalp or of the hair root region, in particular before or after hair treatment, for example during colouring |
| 07/25/2002 | US20020099075 Combination therapy |
| 07/25/2002 | US20020099064 Analgesic combination of oxycodone and T-614 |
| 07/25/2002 | US20020099059 A selective 5-hydroxytriptamine receptor agonist and acetaminophen, non-steroidal anti-inflammatory agents and/or caffeine. |
| 07/25/2002 | US20020099058 Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| 07/25/2002 | US20020099057 Treatment of accidental extravasation of anthracyclines |
| 07/25/2002 | US20020099049 Analgesic combination of oxycodone and meloxicam |
| 07/25/2002 | US20020099046 Atorvastatin or a pharmaceutically acceptable salt thereof and an antihypertensive agent such as a calcium channel blocker, an ACE inhibitor, an A-II antagonist, a diuretic, a beta- or alpha adrenergic receptor blocker |
| 07/25/2002 | US20020099045 Administering a sigma receptor ligand in combination with an antidepressant agent; especially for refractory depression |
| 07/25/2002 | US20020099033 Method and composition for treating sleep apnea |
| 07/25/2002 | US20020099021 Carbetapentane tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, and unproductive cough |
| 07/25/2002 | US20020099020 Oil blend of omega-3- and omega-6- fatty acids; branched amino acid; antioxidant comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof; in a liquid nutritional matrix. |
| 07/25/2002 | US20020099014 Method for treatment of insulin resistance in obesity and diabetes |
| 07/25/2002 | US20020099004 Inhibiting or abolishing the protein cleaving action of plasmin, and inhibiting or abolishing the protein cleaving action of a murine metalloprotease. |
| 07/25/2002 | US20020099003 Also improving vaginal muscle tone and tissue health, preventing vaginal atrophy, preventing vaginal pain during sexual intercourse, and alleviating vaginal itching and dryness; applying to the vagina and/or vulvar region |
| 07/25/2002 | US20020099000 Fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers. |
| 07/25/2002 | US20020098998 P27 prevents cellular migration |
| 07/25/2002 | US20020098582 Differentiated stem cells suitable for human therapy |
| 07/25/2002 | US20020098580 MDM interacting protein and methods of use thereof |
| 07/25/2002 | US20020098544 Polypeptide for use in screening bactericides |
| 07/25/2002 | US20020098540 Novel polypeptides, and nucleic acids encoding the same |